Earnings ·
AbbVie reported that second-quarter 2026 GAAP and adjusted non-GAAP earnings will include a pre-tax acquired IPR&D and…
ABBVAbbVie Inc.
AbbVie reported that second-quarter 2026 GAAP and adjusted non-GAAP earnings will include a pre-tax acquired IPR&D and milestones expense of $291 million, reducing diluted earnings per share by $0.17. Consequently, the company provided updated guidance for the second quarter of 2026 with an adjusted diluted EPS range of $3.57 to $3.61. The full-year 2026 adjusted diluted EPS guidance range, incorporating this expense, is now $13.91 to $14.11. AbbVie is a biopharmaceutical company that discovers, develops, and markets advanced therapies.